Taking Molecular Glue Degraders to New Heights

From understanding surfaces to treating disease

Two Monte Rosa team members smile as they meet over coffee at the office.

Great People Fuel Great Science

At Monte Rosa, we’ve gone beyond boundaries with a team driven by innovation and a passion for medicine. Our experts in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics are not just advancing the field—they're shaping the future of medicine.

At Monte Rosa, our team of scientists

is working together to rapidly advance MGD programs that target undruggable or inadequately drugged targets with unprecedented specificity.

Boston

Recent News

press release

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

read more
press release

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

read more
Boston
321 Harrison Avenue, Suite 900
Boston, MA 02118
United States
+1-617-949-2643
Basel
Monte Rosa Therapeutics AG
WKL-136.3
Klybeckstrasse 191
4057 Basel, Switzerland